Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $152.5, a high estimate of $185.00, and a low estimate of $115.00. Marking an ...

Acadia Pharmaceuticals is working on its next-generation Nuplazid and, for CEO Catherine Owen Adams, the journey is personal.

MMJ-001 Marks a Pharmaceutical First in Cannabis Medicine with FDA-Grade Formulation for a Devastating Neurological Disorder while awaiting final FDA approval for use in clinical trials.

SOM3355 (bevantolol hydrochloride) hit its objectives in a phase 2 trial in patients with Huntington's disease, improving the involuntary, jerky movements known as chorea that are a key symptom of ...

Prilenia Therapeutics is planning to file its Huntington’s disease drug pridopidine in the EU shortly, after mixed results in a phase 3 trial.

Dystonia and chorea are uncommon abnormal movements which can be seen in a wide array of disorders. One quarter of dystonias and essentially all choreas are symptomatic or secondary, the underlying ...

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its second quarter 2025 financial results conference call and webcast for 1:30 p.m. Pacific Time (4:30 p.m. Eastern ...

Xenazine is a prescription drug used to treat chorea in people with Huntington’s disease. Find out about cost, financial assistance, and more.